SEND NEWS ARTICLE TO FRIEND
To Email:
From Email:
News Headline
Adaptive Biotechnologies Launches Clonoseq, a More Sensitive, Accurate Assay to Detect Minimal Residual Disease (MRD) in Blood-Based Cancers.